Supernus Pharmaceuticals Inc (SUPN) VP Victor Vaughn Sells 15,000 Shares

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total transaction of $630,600.00. Following the sale, the vice president now owns 24,344 shares of the company’s stock, valued at approximately $1,023,421.76. The sale was disclosed in a document filed with the SEC, which is available through this link.

Victor Vaughn also recently made the following trade(s):

  • On Friday, January 12th, Victor Vaughn sold 5,750 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $45.03, for a total transaction of $258,922.50.
  • On Tuesday, January 2nd, Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00.

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $46.50 on Thursday. Supernus Pharmaceuticals Inc has a 52-week low of $23.10 and a 52-week high of $50.04. The firm has a market capitalization of $2,191.46, a price-to-earnings ratio of 43.87 and a beta of 1.18.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. The business’s quarterly revenue was up 41.5% compared to the same quarter last year. research analysts predict that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 1,462 shares in the last quarter. Advisor Group Inc. lifted its stake in Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 517 shares in the last quarter. Finally, Flinton Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 88.9% in the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after acquiring an additional 2,240 shares in the last quarter. 98.22% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently commented on SUPN shares. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. FBR & Co began coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price for the company. Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Monday, December 4th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Tuesday, November 7th. Finally, Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $49.90.

WARNING: “Supernus Pharmaceuticals Inc (SUPN) VP Victor Vaughn Sells 15,000 Shares” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/18/victor-vaughn-sells-15000-shares-of-supernus-pharmaceuticals-inc-supn-stock.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply